Raymond James Financial Services Advisors, Inc. Provention Bio, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$69.1 Billion
Q2 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$6.7 - $24.21 $3,095 - $11,185	-462 Reduced 2.72%	16,505 $397,000
Q4 2022 Feb 08, 2023	BUY	$4.52 - $10.57 $76,690 - $179,341	16,967 New	16,967 $179,000
Q1 2021 May 14, 2021	SELL	$10.12 - $19.45 $335,366 - $644,553	-33,139 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$11.79 - $18.94 $70,622 - $113,450	5,990 Added 22.06%	33,139 $561,000
Q3 2020 Nov 04, 2020	SELL	$10.34 - $15.2 $17,495 - $25,718	-1,692 Reduced 5.87%	27,149 $348,000
Q2 2020 Jul 17, 2020	SELL	$7.81 - $17.0 $96,344 - $209,712	-12,336 Reduced 29.96%	28,841 $407,000
Q1 2020 Apr 21, 2020	SELL	$5.42 - $17.75 $9,739 - $31,896	-1,797 Reduced 4.18%	41,177 $379,000
Q4 2019 Feb 12, 2020	BUY	$5.84 - $14.9 $67,796 - $172,974	11,609 Added 37.01%	42,974 $640,000
Q3 2019 Nov 07, 2019	BUY	$6.83 - $13.0 $12,143 - $23,114	1,778 Added 6.01%	31,365 $214,000
Q2 2019 Aug 06, 2019	BUY	$2.3 - $13.79 $68,050 - $408,004	29,587 New	29,587 $358,000

Others Institutions Holding PRVB

# of Institutions

Shares Held

170K

Call Options Held

Put Options Held

Odey Asset Management Group LTD London, X0

170K
Shares

$0
1.36% of portfolio

View Full List

About Provention Bio, Inc.

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

More about PRVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account